165 related articles for article (PubMed ID: 21744473)
1. Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.
Houghton PJ; Lock R; Carol H; Morton CL; Phelps D; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Wozniak AW; Gu Y; Wilson WR; Smith MA
Pediatr Blood Cancer; 2011 Sep; 57(3):443-53. PubMed ID: 21744473
[TBL] [Abstract][Full Text] [Related]
2. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
Jamieson SM; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR
Biochem Pharmacol; 2014 Mar; 88(1):36-45. PubMed ID: 24434189
[TBL] [Abstract][Full Text] [Related]
3. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
[TBL] [Abstract][Full Text] [Related]
4. Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
Abbattista MR; Jamieson SM; Gu Y; Nickel JE; Pullen SM; Patterson AV; Wilson WR; Guise CP
Cancer Biol Ther; 2015; 16(4):610-22. PubMed ID: 25869917
[TBL] [Abstract][Full Text] [Related]
5. Drug-DNA adducts as biomarkers for metabolic activation of the nitro-aromatic nitrogen mustard prodrug PR-104A.
Stornetta A; Deng KK; Danielli S; Liyanage HDS; Sturla SJ; Wilson WR; Gu Y
Biochem Pharmacol; 2018 Aug; 154():64-74. PubMed ID: 29630868
[TBL] [Abstract][Full Text] [Related]
6. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
Singleton RS; Guise CP; Ferry DM; Pullen SM; Dorie MJ; Brown JM; Patterson AV; Wilson WR
Cancer Res; 2009 May; 69(9):3884-91. PubMed ID: 19366798
[TBL] [Abstract][Full Text] [Related]
7. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.
Guise CP; Wang AT; Theil A; Bridewell DJ; Wilson WR; Patterson AV
Biochem Pharmacol; 2007 Sep; 74(6):810-20. PubMed ID: 17645874
[TBL] [Abstract][Full Text] [Related]
8. Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.
Gu Y; Guise CP; Patel K; Abbattista MR; Li J; Sun X; Atwell GJ; Boyd M; Patterson AV; Wilson WR
Cancer Chemother Pharmacol; 2011 Mar; 67(3):543-55. PubMed ID: 20473609
[TBL] [Abstract][Full Text] [Related]
9. Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapy.
Gu Y; Tingle MD; Wilson WR
J Pharmacol Exp Ther; 2011 Jun; 337(3):692-702. PubMed ID: 21427202
[TBL] [Abstract][Full Text] [Related]
10. Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A.
Gu Y; Patterson AV; Atwell GJ; Chernikova SB; Brown JM; Thompson LH; Wilson WR
Mol Cancer Ther; 2009 Jun; 8(6):1714-23. PubMed ID: 19509245
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients.
McKeage MJ; Gu Y; Wilson WR; Hill A; Amies K; Melink TJ; Jameson MB
BMC Cancer; 2011 Oct; 11():432. PubMed ID: 21982454
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors.
Jameson MB; Rischin D; Pegram M; Gutheil J; Patterson AV; Denny WA; Wilson WR
Cancer Chemother Pharmacol; 2010 Mar; 65(4):791-801. PubMed ID: 20012293
[TBL] [Abstract][Full Text] [Related]
13. AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.
Moradi Manesh D; El-Hoss J; Evans K; Richmond J; Toscan CE; Bracken LS; Hedrick A; Sutton R; Marshall GM; Wilson WR; Kurmasheva RT; Billups C; Houghton PJ; Smith MA; Carol H; Lock RB
Blood; 2015 Sep; 126(10):1193-202. PubMed ID: 26116659
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.
Patterson AV; Ferry DM; Edmunds SJ; Gu Y; Singleton RS; Patel K; Pullen SM; Hicks KO; Syddall SP; Atwell GJ; Yang S; Denny WA; Wilson WR
Clin Cancer Res; 2007 Jul; 13(13):3922-32. PubMed ID: 17606726
[TBL] [Abstract][Full Text] [Related]
15. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
Hicks KO; Myint H; Patterson AV; Pruijn FB; Siim BG; Patel K; Wilson WR
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):560-71. PubMed ID: 17869669
[TBL] [Abstract][Full Text] [Related]
16. Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3.
Abbattista MR; Ashoorzadeh A; Guise CP; Mowday AM; Mittra R; Silva S; Hicks KO; Bull MR; Jackson-Patel V; Lin X; Prosser GA; Lambie NK; Dachs GU; Ackerley DF; Smaill JB; Patterson AV
Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959631
[TBL] [Abstract][Full Text] [Related]
17. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
[TBL] [Abstract][Full Text] [Related]
18. Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs, and humans.
Gu Y; Atwell GJ; Wilson WR
Drug Metab Dispos; 2010 Mar; 38(3):498-508. PubMed ID: 20019245
[TBL] [Abstract][Full Text] [Related]
19. Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia.
Guise CP; Abbattista MR; Tipparaju SR; Lambie NK; Su J; Li D; Wilson WR; Dachs GU; Patterson AV
Mol Pharmacol; 2012 Jan; 81(1):31-40. PubMed ID: 21984255
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate pre-prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry.
Patel K; Lewiston D; Gu Y; Hicks KO; Wilson WR
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Sep; 856(1-2):302-11. PubMed ID: 17644498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
